ABSTRACT
Introduction Catheters are an integral part of modern medicine although their use is not without complications. Catheter-related infection triggers a strong inflammatory reaction and has been associated with high morbidity, mortality, and healthcare costs. The clinical diagnosis of catheter-related infection is made difficult by non-specific symptoms. Investigating the alterations in biochemical parameters related to infectious and inflammatory processes in these patients constitute an active line of research. The aim of this study was to investigate factors influencing the plasma concentration of galectin-3 in catheter-bearing patients and to explore its potential usefulness as an index for catheter-related infections.
Methods Circulating concentrations of galectin-3, chemokine (C-C) motif ligand 2, procalcitonin and C-reactive protein were measured in 110 patients with a central venous catheter, 165 patients with a urinary catheter, and 72 control subjects.
Results Catheter-bearing patients had significantly higher concentrations of galectin-3 and the other markers than the control group. We identified chronic kidney disease as an independent determinant of plasma galectin-3 concentrations in patients with a central catheter, and serum creatinine concentration, cardiovascular disease and the number of days the catheter was indwelling as determinants in urinary catheter patients. We also found that measuring galectin-3 in urinary catheter patients with a catheter-related infection was more accurate for diagnosis than the other parameters. At galectin-3 = 15 ng/mL, sensitivity was 90%.
Conclusion We conclude that measurement of galectin-3 concentration may be useful for assessing the inflammatory status of catheter-bearing patients and may contribute to the diagnosis of catheter-related infection in those with a urinary catheter.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by a grant from the Fundacio la Marato de TV3 (201807-10), Barcelona, Spain.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was conducted in accordance with the Declaration of Helsinki, and was approved by the Ethics Committee (Institutional Review Board) of the Hospital Universitari de Sant Joan (12proj2. 10/12/23). All the subjects provided written informed consent to participate in the study on the understanding that anonymity of data was guaranteed.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data are available from the corresponding author upon reasonable request.
Abbreviations
- ACI
- acute concomitant infection
- CCL2
- chemokine (C-C) motif ligand 2
- CRI
- catheterrelated infection
- CRP
- C-reactive protein
- CVC
- central venous catheter
- UC
- urinary catheter
- ROC
- receiver operating characteristics.
